Key characteristics of the emerging variant

SARS-CoV-2 continues to evolve, and health agencies track emerging lineages for changes in spread, immune escape and disease severity. As of the latest WHO monitoring, JN.1 remains a variant of interest, while XFG, NB.1.8.1, PQ.16.1.1 and BA.3.2 are among the variants under monitoring.

Variant prevalence can change quickly between regions and over time. WHO surveillance showed XFG becoming the most prevalent globally in late August 2026, while other monitored lineages declined or remained stable. Prior infection and vaccination may not prevent every infection, but vaccination continues to be important for protection against severe disease.

The symptoms? Not dramatically different, but reports show more people experiencing:

• Severe fatigue

• Headaches

• Throat discomfort

• Less loss of taste and smell than earlier variants

Geographic origin and spread patterns

The current variant landscape includes multiple Omicron-descended lineages rather than a single new strain. WHO tracks these lineages globally and updates their status as surveillance data changes.

Variant prevalence differs by region and can shift over a matter of weeks. WHO sequencing data from August 2026 showed XFG increasing globally, including in the European Region and the Americas, while several other monitored lineages were stable or declining.

How it differs from previous variants

Newer lineages can carry mutations associated with some degree of immune escape, but this does not mean prior vaccination or infection provides no protection. Protection against infection can wane, while vaccination remains important for reducing the risk of severe disease.

Current WHO assessments have not identified additional public-health risk from the variants under monitoring compared with other circulating SARS-CoV-2 variants. Severity and transmission should be interpreted from updated surveillance rather than assumed from lineage changes alone.

Laboratory characteristics do not always translate directly into predictable symptoms or severity in people. The most useful indicators remain real-world surveillance, hospitalization data, vaccine effectiveness and formal risk assessments from public-health agencies.

SARS-CoV-2 continues to evolve, so variant information should be checked against current WHO and national public-health surveillance. This article was refreshed in October 2026 to remove outdated claims and reflect the latest monitoring context.